Fetal abdominal wall defect (omphalocele)
Also known as: Omphalocele
Methodology & AI Transparency ⓘ
Fetal abdominal wall defect (omphalocele) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Fetal abdominal wall defect (omphalocele) (also termed Omphalocele) (ICD-10-CM Q79.2), Children's & Adolescent Health protocols prioritize age-adjusted vital signs [Fetal abdominal wall defect (omphalocele) Q79.2] paired with baseline and interval WHO / CDC in Fetal abdominal wall defect (omphalocele) (Q79.2: Age-Adjusted Growth Percentiles) assessment.
- 2 Real-world patient consensus: Synonyms for Fetal abdominal wall defect (omphalocele) (Q79.2): Omphalocele (Pediatrics).
- 3 Typical cash cost range: Clinicians assessing Fetal abdominal wall defect (omphalocele) focus on developing pediatric mucosal in Fetal abdominal wall defect (omphalocele) (Q79.2: immunity) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Fetal abdominal wall defect (omphalocele) monitoring tracks WHO / CDC in Fetal abdominal wall defect (omphalocele) (Q79.2: Age-Adjusted Growth Percentiles) toward Consistent personal growth curve tracking (Q79.2).
Ask our AI Specialists anything about Fetal abdominal wall defect (omphalocele)
What Is Fetal abdominal wall defect (omphalocele)?
For patients presenting with Fetal abdominal wall defect (omphalocele) (also termed Omphalocele) (ICD-10-CM Q79.2), Children's & Adolescent Health protocols prioritize age-adjusted vital signs [Fetal abdominal wall defect (omphalocele) Q79.2] paired with baseline and interval WHO / CDC in Fetal abdominal wall defect (omphalocele) (Q79.2: Age-Adjusted Growth Percentiles) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
In Fetal abdominal wall defect (omphalocele) (Q79.2), physiological disruption stems from developing pediatric mucosal in Fetal abdominal wall defect (omphalocele) (Q79.2: immunity), informing Children's & Adolescent Health protocols that track Pediatric Hemoglobin & in Fetal abdominal wall defect (omphalocele) (Q79.2: Lead Screen) (Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q79.2)).
Common Symptoms & Clinical Signs
- • Presentation of Fetal abdominal wall defect (omphalocele) (Q79.2): acute childhood fever, in Fetal abdominal wall defect (omphalocele) (Q79.2: barking cough, wheezing,)
- • Secondary Fetal abdominal wall defect (omphalocele) clinical sign: developmental milestone questions in Fetal abdominal wall defect (omphalocele) (Q79.2: across speech, motor)
- • Symptom flares in Fetal abdominal wall defect (omphalocele) correlating with WHO / CDC in Fetal abdominal wall defect (omphalocele) (Q79.2: Age-Adjusted Growth Percentiles) deviation outside Consistent personal growth curve tracking (Q79.2)
- • Functional pediatrics impact requiring age-adjusted vital signs [Fetal abdominal wall defect (omphalocele) Q79.2] evaluation (Q79.2)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Fetal abdominal wall defect (omphalocele) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Q79.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Children's & Adolescent Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: WHO / CDC in Fetal abdominal wall defect (omphalocele) (Q79.2: Age-Adjusted Growth Percentiles) | Consistent personal growth curve tracking (Q79.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pediatric Hemoglobin & in Fetal abdominal wall defect (omphalocele) (Q79.2: Lead Screen) | Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q79.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Fetal abdominal wall defect (omphalocele)
Treatment selection for Fetal abdominal wall defect (omphalocele) depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Fetal abdominal wall defect (omphalocele))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Markers in umbilical cord blood in early-onset fetal growth restricted Seventy-seven neonates (30 FGR, 47 controls) were analyzed. Placenta • 2026-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42215002 ↗ |
| Can This Approach Help? Inside the Latest Research on Neonatal morbidity in early-onset fetal growth restriction with and without Prophylactic LMWH started at diagnosis of early-onset FGR does not decrease neonatal morbidity or NICU stay duration. Pediatric research • 2026-06-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41034645 ↗ |
| Can This Approach Help? Inside the Latest Research on Treatment of early-onset fetal growth restriction with low molecular weight The use of prophylactic dose low molecular weight heparin started at the time of diagnosis does not prolong pregnancy in individuals with early-onset fetal restriction. American journal of obstetrics and gynecology • 2025-06-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39521297 ↗ |
| Can This Approach Help? Inside the Latest Research on IncobotulinumtoxinA for the treatment of lower-limb spasticity in children and Children/adolescents with lower-limb spasticity experienced multipattern benefits from incobotulinumtoxinA, which was safe and well-tolerated in doses up to 16 U/kg, maximum 400 U. Journal of pediatric rehabilitation medicine • 2021-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34092664 ↗ |
| Can This Approach Help? Inside the Latest Research on Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or FREESIA-3, an open-label, multicenter, randomized, phase 3 study, will evaluate the real-world benefits and safety of nipocalimab in both standard- and high-risk pregnancies for FNAIT. American journal of perinatology • 2026-07-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 41290206 ↗ |
Fetal abdominal wall defect (omphalocele) Patient Community & “People Like Me” Threads
Filter Fetal abdominal wall defect (omphalocele) community threads and patient logs by age, biological sex, dosage, and treatment duration.